Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Influenza

Free Subscription 22.09.2025 1 Ann Intern Med 1 Arch Virol 2 J Gen Virol 8 J Infect 3 J Virol 22 PLoS One 2 Proc Natl Acad Sci U S A 81 Vaccine

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Intern Med

1. FELDMAN CH, Santacroce L, Bassett IV, Thaweethai T, et al
   Social Determinants of Health and Risk for Long COVID in the U.S. RECOVER-Adult Cohort.
   Ann Intern Med. 2025 Jul 29. doi: 10.7326/ANNALS-24-01971.
   PubMed         Abstract available
   
   

   
   Arch Virol

2. PUENPA J, Dara S, Vichaiwattana P, Aeemjinda R, et al
   Seasonal dynamics and genetic diversity of human rhinoviruses in patients with acute respiratory infection in Bangkok in 2024.
   Arch Virol. 2025;170:208.
   PubMed         Abstract available
   
   

   
   J Gen Virol

3. DI GENOVA C, Warren CJ, Johnson S, Riccio S, et al
   Pigeons exhibit low susceptibility and poor transmission capacity for H5N1 clade 2.3.4.4b high pathogenicity avian influenza virus.
   J Gen Virol. 2025;106.
   PubMed         Abstract available
   
   
4. PHAN N, Zaytseva Y, Lin CC, Mishra M, et al
   PUM2 binds SARS-CoV-2 RNA and PUM1 mildly reduces viral RNA levels, but neither protein affects progeny virus production.
   J Gen Virol. 2025;106:002152.
   PubMed         Abstract available
   
   

   
   J Infect

5. AHIMBISIBWE G, Greenwood D, Wilkinson KA, Gahir J, et al
   Third exposure to COVID-19 infection or vaccination differentially impacts T Cell responses.
   J Infect. 2025 Aug 21:106598. doi: 10.1016/j.jinf.2025.106598.
   PubMed         Abstract available
   
   
6. LIU B, Song S, Liu W, Hu Y, et al
   Post-COVID-19 multimorbidity incidence by prior vaccination status in people with a pre-existing comorbidity: A population-based cohort study.
   J Infect. 2025;91:106597.
   PubMed         Abstract available
   
   
7. ATTAIANESE F, Trapani S, Agostiniani R, Ambrosino N, et al
   Effectiveness of a targeted infant RSV immunization strategy (2024-2025): A multicenter matched case-control study in a high-surveillance setting.
   J Infect. 2025;91:106600.
   PubMed         Abstract available
   
   
8. DIETL B, Henares D, Cuchi E, Blanco-Fuertes M, et al
   Differential nasopharyngeal microbiota patterns: A Comparative Study of Pneumococcal Pneumonia, COVID-19, and Healthy Adults.
   J Infect. 2025 Aug 14:106589. doi: 10.1016/j.jinf.2025.106589.
   PubMed         Abstract available
   
   
9. LI Z, Wang X, Chen S, Xiong W, et al
   Assessing Global Border Controls in Response to COVID-19 Pandemic Using Real-World Data and Target Trial Emulation.
   J Infect. 2025 Aug 12:106578. doi: 10.1016/j.jinf.2025.106578.
   PubMed         Abstract available
   
   
10. JANANI L, Munro APS, Wright A, Aley PK, et al
    Heterologous COVID-19 vaccine schedule with protein-based prime (NVX-CoV2373) and mRNA boost (BNT162b2) induces strong humoral responses: results from COV-BOOST trial.
    J Infect. 2025 Aug 7:106576. doi: 10.1016/j.jinf.2025.106576.
    PubMed         Abstract available
    
    
11. SYMES R, Keddie SH, Walker J, McKeever T, et al
    Burden of respiratory syncytial virus infection in older adults hospitalised in England during 2023/24.
    J Infect. 2025;91:106570.
    PubMed         Abstract available
    
    
12. GONZALEZ-SANCHEZ A, Andres C, Prats-Mendez I, Pinana M, et al
    Evolutionary dynamics of HRSV following the implementation of nirsevimab immunoprophylaxis in Catalonia (2023-2024).
    J Infect. 2025;91:106567.
    PubMed         Abstract available
    
    

    
    J Virol

13. PAPPAS C, Brock N, Belser JA, Kieran TJ, et al
    Identification of clinical and virological correlates associated with influenza A candidate vaccine virus (CVV) attenuation in a ferret model.
    J Virol. 2025 Sep 17:e0102325. doi: 10.1128/jvi.01023.
    PubMed         Abstract available
    
    
14. LI Q, Cai X, Li X, Zhang Y, et al
    Structural and functional constraints on spike activation and host protease utilization limit cell entry of SARS-CoV-2-related bat coronaviruses.
    J Virol. 2025 Jul 24:e0100725. doi: 10.1128/jvi.01007.
    PubMed         Abstract available
    
    
15. XU Z, Li L, Gu Y, Li D, et al
    CX1/BtSY2 and BANAL-20-52 exhibit broader receptor binding and higher affinities to multiple animal ACE2 orthologs than SARS-CoV-2 prototype.
    J Virol. 2025 Jul 10:e0028325. doi: 10.1128/jvi.00283.
    PubMed         Abstract available
    
    

    
    PLoS One

16. CHOI MJ, Choi WS, Song JY, Cheong HJ, et al
    Estimating the clinical and economic burden of medically attended influenza in South Korea, stratified by age and comorbidity: A five-season hospital-based surveillance data, 2014/15-2018/19.
    PLoS One. 2025;20:e0317643.
    PubMed         Abstract available
    
    
17. EI D, Bradvik G, Lindgren P, Barach P, et al
    Correlations between the prescribing patterns of psychotropic medications and socio-economic factors during the COVID-19 pandemic: A cross-sectional Swedish registry study.
    PLoS One. 2025;20:e0330081.
    PubMed         Abstract available
    
    
18. MARFOH K, Samba A, Okyere E, Fattah AZ, et al
    Post-vaccination SARS-CoV-2 infections among healthcare workers in a tertiary hospital in Ghana.
    PLoS One. 2025;20:e0331971.
    PubMed         Abstract available
    
    
19. BELSHAW Z, Brand CL, O'Neill DG, Packer RMA, et al
    More than just one man and his dog: The many impacts of puppy acquisition on the mental health of families including children in the UK.
    PLoS One. 2025;20:e0331179.
    PubMed         Abstract available
    
    
20. CETIN S, Ulgen A, Sivgin H, Cetin M, et al
    Osmolality as a strong predictor of COVID-19 mortality and its possible links to other biomarkers.
    PLoS One. 2025;20:e0331344.
    PubMed         Abstract available
    
    
21. SUN Y, Yang C
    The influence of investor sentiment on the Chinese stock market amid COVID-19: An event study analysis.
    PLoS One. 2025;20:e0332216.
    PubMed         Abstract available
    
    
22. GIANCOLA M, Mari E, Palmiero M, Burrai J, et al
    Adolescence and online vulnerability: The role of fear of missing out (FoMO): A cross-sectional study during the third wave of the COVID-19 pandemic.
    PLoS One. 2025;20:e0332147.
    PubMed         Abstract available
    
    
23. HE Y, Cheng C, Wang L
    Unmasking the effects of E-leadership on virtual team effectiveness by an integrated fsQCA and NCA method.
    PLoS One. 2025;20:e0331500.
    PubMed         Abstract available
    
    
24. FAZZIO I, Shivalli S, Magill N, Elbourne D, et al
    Support To Rural India's Public Education System (STRIPES2) and impact on numeracy and literacy scores: A cluster randomized trial in rural villages of Madhya Pradesh, India.
    PLoS One. 2025;20:e0330203.
    PubMed         Abstract available
    
    
25. PENG J, Isoni A, Luckman A, Zeitoun H, et al
    How facemasks shape trust in social interactions.
    PLoS One. 2025;20:e0331918.
    PubMed         Abstract available
    
    
26. VISHKIN A, Bkheet E
    Effects of survey administration mode on response profiles are predictable, and robust across countries: Evidence from 29 countries using machine-learning models.
    PLoS One. 2025;20:e0330182.
    PubMed         Abstract available
    
    
27. HERNAWAN B, Duran-Sierra GF, Zarate-Losoya E, Medina-Cetina Z, et al
    A pandemic risk index to improve supply chains decision-making between US and Mexico: A COVID-19 case study.
    PLoS One. 2025;20:e0327526.
    PubMed         Abstract available
    
    
28. TERAKAWA K, Katagiri D, Asai Y, Ishikane M, et al
    A retrospective cohort study evaluating the predictive value of urinary L-FABP combined with the SOFA score for assessing COVID-19 severity.
    PLoS One. 2025;20:e0331558.
    PubMed         Abstract available
    
    
29. WANJIKU P, Orindi B, Kimotho J, Sayed S, et al
    Induction of an early IFN-gamma cellular response and high plasma levels of SDF-1alpha are inversely associated with COVID-19 severity and residence in rural areas in Kenyan patients.
    PLoS One. 2025;20:e0316967.
    PubMed         Abstract available
    
    
30. LI Y, Lu X, Fu J, Yang F, et al
    Influence of SARS-CoV-2 infection before and during organogenesis on embryo implantation and development outcomes: A prospective cohort observational study.
    PLoS One. 2025;20:e0328743.
    PubMed         Abstract available
    
    
31. CLAVERIE D, Duffaud A, Pellissier S, Jacob S, et al
    Influence of mindfulness and coping flexibility in the early phases of burnout development in intensive care unit healthcare workers during the COVID-19 pandemic.
    PLoS One. 2025;20:e0328064.
    PubMed         Abstract available
    
    
32. YOON CS, Park HY, Park HK, Lee JK, et al
    The influence of pneumococcal positivity on clinical outcomes among patients hospitalized with COVID-19: A retrospective cohort study.
    PLoS One. 2025;20:e0329474.
    PubMed         Abstract available
    
    
33. BONILLA Y, High D, Acosta Rullan J, Tabba J, et al
    Body mass index and critical care outcomes in hospitalized COVID-19 patients-A national cohort study.
    PLoS One. 2025;20:e0329779.
    PubMed         Abstract available
    
    
34. WASILEWSKI MB, Leighton J, Reis L, Vijayakumar A, et al
    Coping with stressful life disruptions due to long COVID: A qualitative study.
    PLoS One. 2025;20:e0329831.
    PubMed         Abstract available
    
    
35. TCHOUA PP, Patel S, Starr AS, Rairigh R, et al
    Implementation of oral health evidence-based practices in early care education settings across the U.S. during different COVID-19 periods.
    PLoS One. 2025;20:e0323396.
    PubMed         Abstract available
    
    
36. GUTMANIS I, Coleman BL, Ramsay K, Maunder R, et al
    Changes in emotional distress among Ontario education workers during the COVID-19 pandemic: 2021-2023.
    PLoS One. 2025;20:e0330442.
    PubMed         Abstract available
    
    
37. HERNANDEZ GT, Menendez D, Yoo SH, Klapper RE, et al
    "What happens when you get corona?": Children's questions and parental responses about the COVID-19 pandemic.
    PLoS One. 2025;20:e0330506.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

38. SWINGLE KL, Hamilton AG, Han X, Liao KC, et al
    Circular RNA lipid nanoparticle vaccine against SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2025;122:e2505718122.
    PubMed         Abstract available
    
    
39. URMI T, Pant B, Dewey G, Quintana-Mathe A, et al
    Characterizing population-level changes in human behavior during the COVID-19 pandemic in the United States.
    Proc Natl Acad Sci U S A. 2025;122:e2500655122.
    PubMed         Abstract available
    
    

    
    Vaccine

40. SHEN Y, Sung MH, Ge Y, Chen Y, et al
    Predicting influenza vaccine-elicited antibody responses with practical point systems.
    Vaccine. 2025;64:127737.
    PubMed         Abstract available
    
    
41. ODAGIRI T, Yoshino N, Sasaki Y, Ishikawa S, et al
    Polymyxin B as a novel mucosal adjuvant for the intranasal whole inactivated influenza vaccine.
    Vaccine. 2025;64:127750.
    PubMed         Abstract available
    
    
42. LANE A, Quach HQ, Ovsyannikova IG, Kennedy RB, et al
    High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014-2022 seasons.
    Vaccine. 2025 Sep 12:127677. doi: 10.1016/j.vaccine.2025.127677.
    PubMed         Abstract available
    
    
43. OKOLI GN, Murphy C, Mak L, Cheng SMS, et al
    Estimates of SARS-CoV-2 vaccine effectiveness against outpatient medically attended SARS-CoV-2 infection from April 2023 through August 2024 in Hong Kong: A test-negative design study.
    Vaccine. 2025;63:127687.
    PubMed         Abstract available
    
    
44. DEGIUSEPPE JI
    Comprehensive assessment of the impact of universal rotavirus vaccination program on the burden of diarrheal disease in children after 10 years of implementation in Argentina.
    Vaccine. 2025;63:127681.
    PubMed         Abstract available
    
    
45. MORGAN JC, Kornides ML, Lee J, Fishman J, et al
    Different vaccination debunking interventions: a randomized, controlled experiment estimating "backfiring" and positive effects.
    Vaccine. 2025;62:127463.
    PubMed         Abstract available
    
    
46. HATZL S, Posch F, Schulz E, Uhl B, et al
    Altered immune responses to mRNA vaccination against SARS-COV-2 are characterized by an impaired cross-talk between humoral and T-cellular immune compartments in patients with hematologic diseases.
    Vaccine. 2025;63:127666.
    PubMed         Abstract available
    
    
47. KITAMURA N, Tomo Y, Okuyama M, Ueda K, et al
    COVID-19 vaccine effectiveness and duration of protection among children and adolescents: A retrospective cohort study in 11 large cities in Japan.
    Vaccine. 2025;63:127656.
    PubMed         Abstract available
    
    
48. FU JYL, Syed Omar SF, Rajasuriar R, Kukreja A, et al
    Longitudinal dynamics of immune responses after mRNA and inactivated COVID-19 vaccination, boosters, and breakthrough infections in Malaysia.
    Vaccine. 2025;63:127657.
    PubMed         Abstract available
    
    
49. COSGROVE S, Hider P, Anglemyer A, Walls T, et al
    HPV vaccination in Aotearoa New Zealand: Impact of a school-based program on adolescent vaccine coverage.
    Vaccine. 2025;63:127637.
    PubMed         Abstract available
    
    
50. KORVES C, Kulldorff M, Balajee AS, Smith J, et al
    Innovative use of self-controlled methods for the evaluation of waning effectiveness of the COVID-19 monovalent third dose: comparison with a test-negative design.
    Vaccine. 2025;63:127658.
    PubMed         Abstract available
    
    
51. WARD JK, Youssef R, Peretti-Watel P
    Different vaccines, different trust issues? Disentangling the effect of trust in various institutions using dominance analysis.
    Vaccine. 2025;63:127668.
    PubMed         Abstract available
    
    
52. LI G, Marchevsky NG, Macaulay G, Aley P, et al
    Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006).
    Vaccine. 2025;62:127597.
    PubMed         Abstract available
    
    
53. GROOM HC, Kuntz JL, Varga AM, Smith N, et al
    Parental intent to vaccinate children with the updated 2023-2024 COVID-19 vaccine.
    Vaccine. 2025;63:127618.
    PubMed         Abstract available
    
    
54. LOUTH J, Holland A, Chum C, Morgan L, et al
    Understanding the immunity gap for serogroup B invasive meningococcal disease due to non-pharmaceutical interventions during the Covid-19 pandemic.
    Vaccine. 2025;63:127647.
    PubMed         Abstract available
    
    
55. CIESLA AA, Mak J, Godoshian A, Smith ZR, et al
    Symptom reporting and vaccination status among SARS-CoV-2-positive encounters - Increasing Community Access to Testing, Treatment, and Response program, United States, September 2023-August 2024.
    Vaccine. 2025;63:127635.
    PubMed         Abstract available
    
    
56. BRUCKER A, Hurst JH, O'Brien EC, Anderson D, et al
    An analytic approach considering two temporal mechanisms driving breakthrough viral infections after vaccination.
    Vaccine. 2025;63:127638.
    PubMed         Abstract available
    
    
57. TSCHERNE A, Sun W, Liu STH, Krammer F, et al
    Mucosal COVID-19 vaccines in clinical development.
    Vaccine. 2025;63:127602.
    PubMed         Abstract available
    
    
58. LUONG NGUYEN LB, Magloire L, Francois A, Billard D, et al
    Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.
    Vaccine. 2025;63:127633.
    PubMed         Abstract available
    
    
59. SHAW CA, Stewart-Jones GBE, Jorquera P, Narayanan E, et al
    Design and preclinical assessment of mRNA-1345 prefusion F glycoprotein-encoding mRNA vaccine for respiratory syncytial virus.
    Vaccine. 2025;63:127589.
    PubMed         Abstract available
    
    
60. KARRAS J, Harrison M, Danchin M, Kaufman J, et al
    Supporting dialogue amongst multicultural communities: Exploring the role of vaccine champions.
    Vaccine. 2025;63:127629.
    PubMed         Abstract available
    
    
61. MORSTEAD T, Loo N, Sin NL, DeLongis A, et al
    COVID-19 hoax belief endorsement and its implications for vaccine uptake: Investigating the role of perceived threat.
    Vaccine. 2025;63:127630.
    PubMed         Abstract available
    
    
62. BUHL C, Jacobsen R, Traulsen JM, Andersen A, et al
    Validation of the Danish translation of the vaccination attitudes examination (VAX) scale.
    Vaccine. 2025;62:127620.
    PubMed         Abstract available
    
    
63. VARISKALLIO S, Moustgaard H, Remes H, Martikainen P, et al
    Association of parental education with adolescents' COVID-19 vaccine uptake: A nationwide register-based study in Finland.
    Vaccine. 2025;63:127615.
    PubMed         Abstract available
    
    
64. GOLLUB EL, Myszkowski N, Xi M, Boyraz G, et al
    Correlates of higher trust in public health officials: results from a representative cohort of private university undergraduates.
    Vaccine. 2025;63:127610.
    PubMed         Abstract available
    
    
65. JEONG NY, Cho S, Lim E, Lee JR, et al
    COVID-19 vaccination and the risk of abnormal uterine bleeding: A nationwide self-controlled case series study.
    Vaccine. 2025;63:127619.
    PubMed         Abstract available
    
    
66. IZQUIERDO G, Villena R, Cabrera C, Albornoz J, et al
    Safety of timely immunization with nirsevimab in hospitalized preterm infants.
    Vaccine. 2025;63:127591.
    PubMed         Abstract available
    
    
67. BAUR C, Saperstein SL, Griffis RL, Vazquez C, et al
    Implementing a co-design approach to facilitate a COVID-19 vaccination rapid response.
    Vaccine. 2025;62:127585.
    PubMed         Abstract available
    
    
68. LINDSEY KM, Farrell Z, Tutino R, Kowalski-Dobson T, et al
    From first infection to reinfection: Comparing Nucleocapsid antibody kinetics in vaccinated and unvaccinated adults.
    Vaccine. 2025;62:127593.
    PubMed         Abstract available
    
    
69. VARMA A, Andrews NJ, Carazo S, Walter K, et al
    Analytical approaches and examples of addressing time-varying factors in COVID-19 vaccine effectiveness studies: Report from a meeting of the World Health Organization.
    Vaccine. 2025;62:127567.
    PubMed         Abstract available
    
    
70. ROBERTS C, Top KA, Henaff L, Tunis M, et al
    Exploring off-label vaccine use: a survey of the global national immunization technical advisory group network.
    Vaccine. 2025;62:127581.
    PubMed         Abstract available
    
    
71. BHAT S, Basak P, Verma S, Siddiqui K, et al
    Type 2 diabetes compromises SARS-CoV-2-specific immunological memory following ChAdOx1 nCoV-19 vaccination.
    Vaccine. 2025;62:127604.
    PubMed         Abstract available
    
    
72. HUNTER OF, McClymont E, Lau O, Bettinger JA, et al
    Knowledge gaps and research priorities regarding vaccination in pregnancy: A Canadian perspective from the prevention of infections in the maternal-infant dyad (PRIMED) consortium.
    Vaccine. 2025;62:127594.
    PubMed         Abstract available
    
    
73. LUVIRA V, Lawpoolsri S, Phumratanaprapin W, Jongkaewwattana A, et al
    Immune responses to a heterologous booster with mRNA based COVID-19 vaccine after priming with an inactivated Newcastle disease virus recombinant vaccine expressing the SARS-CoV-2 spike protein (NDV-HXP-S).
    Vaccine. 2025;62:127601.
    PubMed         Abstract available
    
    
74. VASILIADIS S, Cook J, Nissan K, Cook W, et al
    Vaccine misinformation among Arabic-speakers in Australia and the audience and appetite for a game-based intervention.
    Vaccine. 2025;62:127599.
    PubMed         Abstract available
    
    
75. KILLANDER MOLLER I, Hedberg P, Wagner P, Sparen P, et al
    Sociodemographic factors influencing SARS-CoV-2 vaccination uptake in people with and without HIV: Insights from a Swedish Nationwide cohort.
    Vaccine. 2025;62:127580.
    PubMed         Abstract available
    
    
76. NUZHATH T, Khobragade N, Regan AK, Pinkney JA, et al
    Pregnant women's perceptions of RSVpreF vaccine and Nirsevimab for infant RSV prevention.
    Vaccine. 2025;62:127590.
    PubMed         Abstract available
    
    
77. IMHOF C, Liu S, Messchendorp AL, Sanders JF, et al
    The phenotype and functionality of spike-specific CD4(+) T cells after COVID-19 vaccination associates with time after transplantation in transplant recipients.
    Vaccine. 2025;62:127600.
    PubMed         Abstract available
    
    
78. JAYARAJ VJ, Husin M, Tok PSK, Ismail MZH, et al
    Assessing the relative vaccine effectiveness of a fourth COVID-19 dose on hospitalization in Malaysia amidst evolving omicron variants: An emulated target trial.
    Vaccine. 2025;62:127569.
    PubMed         Abstract available
    
    
79. SIU JY
    Barriers to COVID-19 vaccinations and moral struggle among nurses in a Chinese community: A critical medical anthropology analysis.
    Vaccine. 2025;62:127574.
    PubMed         Abstract available
    
    
80. LIDSTROM AK, Albinsson B, Sund F, Lindback J, et al
    Adverse drug reactions following SARS-CoV-2 vaccination of 3805 healthcare workers cause substantial sick-leave and are correlated to vaccine regimen, age, sex and serological response.
    Vaccine. 2025;62:127553.
    PubMed         Abstract available
    
    
81. AHSAN F, Rahmawati NY, Dachlan EG, Alditia FN, et al
    Memory T cell reactivity to a broad range of conserved SARS-CoV-2-derived ORF1ab epitopes in first wave COVID-19 convalescents.
    Vaccine. 2025;62:127571.
    PubMed         Abstract available
    
    
82. OSMENAJ T, van Roon A, Labuschagne L, Pijpers J, et al
    Determinants for not keeping up to date with COVID-19 vaccination in the 2023 vaccination round among medical risk groups, the Netherlands.
    Vaccine. 2025;62:127561.
    PubMed         Abstract available
    
    
83. XU S, Sy LS, Contreras R, Powers DA, et al
    Differences in COVID-19 XBB.1.5 vaccination coverage: A decomposition analysis across racial and ethnic groups in a large U.S. healthcare system.
    Vaccine. 2025;62:127577.
    PubMed         Abstract available
    
    
84. KURIYAMA K, Murakami K, Sugiura K, Sakui S, et al
    One-year follow-up of the immunogenicity and safety of a first and second booster dose of the NVX-CoV2373 (TAK-019) vaccine in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Final report of a phase 3 ope
    Vaccine. 2025;62:127562.
    PubMed         Abstract available
    
    
85. MORO PL, Getahun A, Romanson B, Marquez P, et al
    Safety monitoring of Pfizer's Respiratory Syncytial Virus Vaccine in pregnant women in the Vaccine Adverse Event Reporting System (VAERS), 2023-2024, United States.
    Vaccine. 2025;62:127497.
    PubMed         Abstract available
    
    
86. SCAIOLI G, Martella M, Moro GL, Mara A, et al
    Assessing vaccination intentions and perceptions among pregnant women in Italy: A multicenter cross-sectional study in the context of mandatory policies and the COVID-19 pandemic.
    Vaccine. 2025;62:127528.
    PubMed         Abstract available
    
    
87. FORTUNATO F, Martinelli D, Ascatigno L, Campanozzi A, et al
    Cost of universal immunization with Nirsevimab vs. standard of practice for infants in their first RSV season. Foggia District, Italy, 2023-2024.
    Vaccine. 2025;62:127550.
    PubMed         Abstract available
    
    
88. MOREIRA J, Patino EG, Braga PE, Pacheco P, et al
    Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac) in Brazilian healthcare professionals: The PROFISCOV trial.
    Vaccine. 2025;62:127559.
    PubMed         Abstract available
    
    
89. GENOVA P, Phung CF, Dickens BL, Lim JM, et al
    Trust in government, science, and vaccine confidence in Southeast Asia: A latent profile analysis.
    Vaccine. 2025;62:127536.
    PubMed         Abstract available
    
    
90. FEDELE G, Schiavoni I, Trentini F, Leone P, et al
    Six-month follow-up of antibody response to bivalent mRNA SARS-CoV-2 vaccine booster in healthcare workers.
    Vaccine. 2025;62:127524.
    PubMed         Abstract available
    
    
91. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
    Comparative effectiveness of one versus two doses of COVID-19 vaccines in Qatar: Evidence of converging protection over time.
    Vaccine. 2025;62:127556.
    PubMed         Abstract available
    
    
92. KANG Y, Zhang F, Vogt TM
    Parental attitudes, beliefs, and experiences related to pediatric COVID-19 vaccination.
    Vaccine. 2025;62:127043.
    PubMed         Abstract available
    
    
93. DIRAY-ARCE J, Chang AC, Moradipoor S, Amodio D, et al
    Longitudinal Meta-cohort study protocol using systems biology to identify vaccine safety biomarkers.
    Vaccine. 2025;62:127504.
    PubMed         Abstract available
    
    
94. XU S, Sy LS, Hong V, Qian L, et al
    Tinnitus risk after COVID-19 XBB.1.5 vaccination: A self-controlled case series study.
    Vaccine. 2025;62:127548.
    PubMed         Abstract available
    
    
95. SALOMAO MDG, de Almeida Leitao Curimbaba C, Braga PE, Franca JID, et al
    Long-term efficacy and immune response of CoronaVac in Brazilian health care workers: Insights from PROFISCOV unblinded trial.
    Vaccine. 2025;62:127527.
    PubMed         Abstract available
    
    
96. VAN DER WEG W, von Kreijfelt G, Davidson L, Zwaveling J, et al
    Strengthening spontaneous reporting-based signal detection during a pandemic with cases from electronic health records using a natural language processing tool.
    Vaccine. 2025;62:127549.
    PubMed         Abstract available
    
    
97. ANDERSEN KM, Ahi T, Mateus JS, Yu T, et al
    2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims.
    Vaccine. 2025;62:127534.
    PubMed         Abstract available
    
    
98. SAIAG E, Shalit R, Alcalay Y, Hasday I, et al
    Cellular and humoral immune responses to SARS-CoV2, comparing previously infected individuals who received one vaccine dose to uninfected individuals after three vaccine doses: A case-control study.
    Vaccine. 2025;62:127525.
    PubMed         Abstract available
    
    
99. PERESON MJ, Badano MN, Sabbione F, Keitelman I, et al
    Evaluation of T cell immune memory response after BBIBP-CorV, gam-COVID-Vac, and heterologous gam-COVID-Vac /mRNA-1273 COVID-19 vaccination schemes against different SARS-CoV-2 variants.
    Vaccine. 2025;62:127526.
    PubMed         Abstract available
    
    
100. VISKUPIC F, Wiltse DL, Djira G
     RSV vaccine uptake among seniors: A path analysis approach.
     Vaccine. 2025;62:127505.
     PubMed         Abstract available
     
     
101. SHETTY AN, Kattan GS, Javed M, Pearce C, et al
     Validating community concerns of menstrual changes associated with COVID-19 vaccination using a self-controlled case series analysis of real-world data.
     Vaccine. 2025;62:127511.
     PubMed         Abstract available
     
     
102. DALEXIS RD, Muray M, Kibret TC, Farahi SMMM, et al
     Factors related to COVID-19 vaccine effectiveness perception in racially diverse adults in Canada.
     Vaccine. 2025;62:127498.
     PubMed         Abstract available
     
     
103. DIONNE M, Sauvageau C, Ward JK, Sylvain-Morneau J, et al
     COVID-19 vaccine hesitancy and perceived post-vaccination adverse event: Findings from a cross-sectional survey.
     Vaccine. 2025;62:127529.
     PubMed         Abstract available
     
     
104. MUNOZ FM, Kampmann B, Stergachis A, Chaudhary M, et al
     A template tool for the evaluation of vaccines for emerging pathogens to be used for pregnant and breast-feeding women.
     Vaccine. 2025;62:127513.
     PubMed         Abstract available
     
     
105. GWAK E, Choe SA, Kim K, Bolormaa E, et al
     Real-world effectiveness of NVX-CoV2373 and BNT162b2 mRNA COVID-19 vaccination in South Korea.
     Vaccine. 2025;62:127496.
     PubMed         Abstract available
     
     
106. GASHTI AB, Patel M, Chahal PS, Hrapovic S, et al
     Purification and functional characterization of gag-spike virus-like particles: Process optimization for efficient vaccine production.
     Vaccine. 2025;62:127500.
     PubMed         Abstract available
     
     
107. BROAD J, Letley L, Adair G, Walker J, et al
     An England-wide survey on attitudes towards antenatal and infant immunisation against respiratory syncytial virus amongst pregnant and post-partum women.
     Vaccine. 2025;62:127482.
     PubMed         Abstract available
     
     
108. GREENBERG BM, Minna JD, Gerber DE, Hernandez RS, et al
     SARS-CoV-2 vaccine failure rates and predictors of immune response in a diverse immunocompromised patient population.
     Vaccine. 2025;62:127473.
     PubMed         Abstract available
     
     
109. MOHANTY S, Zurovac J, Barna M, Cossrow N, et al
     Changes in pneumococcal vaccination disparities by area-level social vulnerability during the COVID-19 pandemic among Medicare and Medicaid enrollees.
     Vaccine. 2025;62:127452.
     PubMed         Abstract available
     
     
110. LIN J, Dai Z, Li C, He WQ, et al
     Change in herpes zoster vaccination uptake before and during the COVID-19 pandemic in the United States older adults.
     Vaccine. 2025;62:127503.
     PubMed         Abstract available
     
     
111. ZLOTNICK C, Castel OC
     The predictors of full, partial and no COVID-19 vaccination among immigrants and non-immigrants.
     Vaccine. 2025;62:127484.
     PubMed         Abstract available
     
     
112. MURATA M, Matsumoto Y, Shimono N
     Comparison of SARS-CoV-2 antibody responses following the second dose of BNT162b2 and mRNA-1273 vaccines in people living with HIV-1.
     Vaccine. 2025;62:127457.
     PubMed         Abstract available
     
     
113. WAGNER SB, Rincon M, Keen KE, Hawk GS, et al
     SARS-CoV-2 breakthrough infection during pregnancy preferentially elicits IgG4 response and enhanced placental-transfer.
     Vaccine. 2025;62:127476.
     PubMed         Abstract available
     
     
114. SANO K, Miyakawa K, Kato H, Kimura Y, et al
     Neutralizing antibody evasion of SARS-CoV-2 JN.1 derivatives KP.3, KP.3.1.1, LB.1, and XEC.
     Vaccine. 2025;62:127472.
     PubMed         Abstract available
     
     
115. ABEL ZDV, Roope LSJ, Violato M, Clarke PM, et al
     Accuracy of online surveys in predicting COVID-19 uptake and demand: A cohort study investigating vaccine sentiments and switching in 13 countries from 2020 to 2022.
     Vaccine. 2025;62:127450.
     PubMed         Abstract available
     
     
116. BAUSSANO I, Tenet V, Baghdasarova K, Harutyunyan Z, et al
     HPV burden in Armenia among unvaccinated women: a series of cross-sectional population-based prevalence surveys.
     Vaccine. 2025;62:127405.
     PubMed         Abstract available
     
     
117. SPRACKLEN TF, Day J, Van Der Ross H, Butters C, et al
     Humoral, T cell and immune gene expression responses to SARS-CoV-2 vaccination in a small group of children with previous MIS-C.
     Vaccine. 2025;62:127461.
     PubMed         Abstract available
     
     
118. SCHMITT MM, Rossler A, Netzl A, Knabl L, et al
     Exposure to two antigenically distinct SARS-CoV-2 variants broadens neutralization patterns.
     Vaccine. 2025;62:127459.
     PubMed         Abstract available
     
     
119. MIHIN HUSKIC I, Bensic M, Kretonic K, Miskulin I, et al
     Duration of protection from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) after primary homologous vaccination or first infection.
     Vaccine. 2025;62:127440.
     PubMed         Abstract available
     
     
120. CUTLAND CL, Gutu K, Yun JA, Izu A, et al
     Lessons learnt during establishment of COVID-19 active vaccine safety surveillance in nine African countries.
     Vaccine. 2025;62:127441.
     PubMed         Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Influenza is free of charge.